Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer

Trial Profile

Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Pembrolizumab (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 03 Apr 2017 Planned initiation date changed from 30 Apr 2017 to 30 Jun 2017.
    • 25 Jan 2017 Planned initiation date changed from 1 Feb 2017 to 30 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top